Iovance Biotherapeutics, Inc. (IOVA) News
Follow Iovance Biotherapeutics, Inc. (IOVA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 46 public stories across 20 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Iovance shares fall more than 32% after updated lung cancer trial results
Shares fell more than 32% on Thursday, putting the stock on track for its worst session since May 2025. The sell-off followed updated lung cancer trial results.
EQUITY | Oct 29, 2026, 03:11 PM UTC
M
Iovance Reports 24.6% Response Rate for Lifileucel in Lung Cancer Trial
EQUITY | Oct 29, 2026, 11:11 AM UTC
M
Iovance Shares Jump 12% in Extended Trading
Iovance Biotherapeutics shares rose 12% in extended trading Wednesday as an upcoming lung-cancer data presentation fueled optimism about its cell therapy beyond melanoma.
EQUITY | Oct 29, 2026, 12:57 AM UTC
M
Iovance Biotherapeutics to Report Third-Quarter Results Nov. 5
Iovance Biotherapeutics said it will report third-quarter 2026 financial results and corporate updates on Thursday, November 5, 2026.
EQUITY | Oct 27, 2026, 11:04 AM UTC
L
Iovance Lifileucel Shows 50% Response Rate in Sarcoma Pilot Trial
Iovance reported a 50% response rate for lifileucel in a soft tissue sarcoma pilot trial.
EQUITY | Oct 26, 2026, 11:10 AM UTC
M
Iovance Reports Phase 2 Melanoma Data With 62.5% ORR
Final Phase 2 data showed a 62.5% confirmed overall response rate and 29.2% complete response rate with one-time lifileucel plus pembrolizumab in frontline advanced melanoma. Median overall survival was not reached at 50
EQUITY | Oct 23, 2026, 02:17 PM UTC
H
Transcript: Iovance Biotherapeutics Q2 2026 Earnings Conference Call
Iovance Biotherapeutics (NASDAQ: IOVA ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you API
LIVE | Oct 06, 2026, 08:00 AM UTC
H
Iovance Biotherapeutics Stock Pauses After Hitting New 52-Week High: What's Going On?
Shares of Iovance Biotherapeutics Inc. (NASDAQ: IOVA ) are trading flat Wednesday morning, taking a breather after Tuesday’s surge which pushed the stock to a new 52-week high. Here’s what investors need to know. Iovance
LIVE | Sep 30, 2026, 02:28 PM UTC
L
Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
Biotech stocks trailed the S&P 500 and Nasdaq-100 in September, yet Iovance Biotherapeutics (IOVA) and ImmunityBio (IBRX) bucked the sector’s decline, while Sellas Life Sciences (SLS) awaited key leukemia data and Vanda
NEWS | Sep 30, 2026, 03:48 AM UTC
L
Dow, S&P 500, Nasdaq Futures Mixed As 30-Year Yield Climbs Higher: CAPR, IOVA, DKNG, TTD In Focus
U.S. stock futures were trading mixed in the overnight session late Tuesday as long-dated bond yields eased back marginally after climbing to multi-decade highs during the day.As of 11:09 p.m. EDT, Dow futures were up 0.
EQUITY | Sep 30, 2026, 03:39 AM UTC
L
Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?
Iovance Biotherapeutics (IOVA), AbCellera Biologics (ABCL) and CrowdStrike Holdings (CRWD) hit fresh 52-week highs on Tuesday as investors responded to stronger business outlooks, analyst support and AI-driven cybersecur
EQUITY | Sep 30, 2026, 02:57 AM UTC
H
Fair Issac Corp., Iovance Biotherapeutics, Stablecoin Development Corp., Carnival Corp. and Micron: Why These 5 Stocks Are on Investors' Radars Today
Major U.S. indices ended lower on Tuesday, with the Dow Jones Industrial Average falling 0.26% to 51,349.92, the S&P 500 declining 0.17% to 7,670.84, and the Nasdaq slipping 0.09% to 26,797.54. These are the top stocks t
LIVE | Sep 30, 2026, 01:39 AM UTC
H
Iovance Biotherapeutics’ Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock Soars
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ) shares are trading higher on Tuesday as the company raises full-year 2026 revenue guidance, bucking a -0.8% slide in the Healthcare sector even as the S&P 500 is down 0.10%.
LIVE | Sep 29, 2026, 05:08 PM UTC
H
Iovance Stock Surges as Strong Melanoma Drug Demand Drives Growth — Barrons.com
By Ty RoushShares of Iovance Biotherapeutics surged Tuesday after the biotech company raised its fiscal-year revenue guidance, thanks to rising demand for a pair of melanoma treatments.Iovance stock rose 28% to $14.06, p
EARNINGS | Sep 29, 2026, 04:06 PM UTC
H
Crude Oil Down 1%; US Job Openings Fall In August
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 50 points on Tuesday. The Dow traded down 0.65% to 51,144.93 while the NASDAQ fell 0.21% to 26,763.71. The S&P 500 also fell, drop
LIVE | Sep 29, 2026, 04:01 PM UTC
L
Iovance Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 29, 2026, 02:48 PM UTC
H
HC Wainwright & Co. maintains Buy rating on Iovance Biotherapeutics, $20 price target
HC Wainwright & Co. maintained their Buy rating on Iovance Biotherapeutics's stock with a price target of $20.00.The price target implies an upside of 82.0% from the Sep 28 close of $10.99.Key takeaways from the analyst
EARNINGS | Sep 29, 2026, 02:37 PM UTC
H
CarMax Posts Upbeat Q2 Earnings, Joins Iovance Biotherapeutics, Perella Weinberg Partners And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index falling over 100 points on Tuesday. Shares of Carmax Inc (NYSE: KMX ) rose sharply after the company reported better-than-expected second-quarter financial results. CarMax
LIVE | Sep 29, 2026, 02:26 PM UTC
L
IOVA Stock Hits Over 2-Year Highs — Why Iovance Raised Its FY2026 Revenue Outlook
Shares of Iovance Biotherapeutics (IOVA) surged to their highest levels in more than two years on Tuesday, after the biotech firm raised its full-year revenue outlook, citing stronger U.S. demand for its cancer treatment
EARNINGS | Sep 29, 2026, 02:15 PM UTC
H
Iovance Biotherapeutics Stock Gains After Raising FY Revenue Guidance on Demand for Melanoma Treatments
By Kelly CloonanShares of Iovance Biotherapeutics rose after the company boosted its full-year revenue forecast, citing strong demand for two melanoma treatments.The stock gained 20% to $13.17 in premarket trading on Tue
EARNINGS | Sep 29, 2026, 01:33 PM UTC
H
Iovance Biotherapeutics shares are trading higher after the company raised its FY26 revenue guidance.
Iovance Biotherapeutics shares are trading higher after the company raised its FY26 revenue guidance.
LIVE | Sep 29, 2026, 11:58 AM UTC
H
Iovance Raises 2026 Revenue Guidance to $410—$420M on Strong Amtagvi, Proleukin Demand
Iovance raised full year 2026 revenue guidance to $410 to $420 million, driven by strong U.S. demand for Amtagvi and Proleukin.Key Highlights:Original SEC Filing: IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ] - 8-K - Sep. 29, 2
EARNINGS | Sep 29, 2026, 11:13 AM UTC
H
Iovance Biotherapeutics, Inc. (IOVA) Raises 2026 Revenue Guidance to $410—$420M
Iovance raised its 2026 total revenue guidance to $410—$420M, up ~$55M at the midpoint from $350—$370M, citing strong U.S. demand for Amtagvi and Proleukin. The update implies nearly 60% annual revenue growth.Material De
EARNINGS | Sep 29, 2026, 11:09 AM UTC
H
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
New Guidance Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 MillionStrong U.S. Demand for Amtagvi and Proleukin Drives Increased OutlookPHILADELPHIA, Sept. 29, 2026 (GLOBE NEWS
EARNINGS | Sep 29, 2026, 11:08 AM UTC
H
Iovance Raises FY2026 Total Revenue Guidance From $350M-$370M To $410M-$420M
Iovance Raises FY2026 Total Revenue Guidance From $350M-$370M To $410M-$420M
LIVE | Sep 29, 2026, 11:03 AM UTC
L
Iovance Biotherapeutics Raises 2026 View To Rev $410M-$420M >IOVA
Iovance Biotherapeutics Raises 2026 View To Rev $410M-$420M >IOVA
NEWS | Sep 29, 2026, 11:02 AM UTC
L
Iovance Biotherapeutics Price Target Announced at $15.00/Share by Goldman Sachs
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 02:05 PM UTC
L
IOVA - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
IOVA - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
NEWS | Sep 18, 2026, 09:10 PM UTC
M
IOVA jumps 21% in four sessions as Barclays cites upside
IOVance Biotherapeutics (IOVA) shares have risen more than 21% over the past four sessions. Barclays expects the rally to continue as investors await an important lung cancer update; stock was up nearly 2% in pre-market
EQUITY | Sep 17, 2026, 11:59 AM UTC
M
Iovance says clear line of sight to profitability
Iovance Biotherapeutics says record Amtagvi sales underpin a “clear line of sight to profitability” as it prepares for year-end data and trial updates.
EQUITY | Sep 15, 2026, 11:01 PM UTC
L
Biotech Stocks At 52-Week Highs - NUTX +8%, IOVA +7%, ATRC, CNC, CON
WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on September 15, 2026, driven by the gain on certain clinical or financial results.Nutex Health Inc. (NUTX)Nutex Health functions as a healthcare
EARNINGS | Sep 15, 2026, 07:40 AM UTC
L
Iovance Biotherapeutics to present at upcoming conferences
Iovance Biotherapeutics announced that senior leadership will present at upcoming conferences.
EQUITY | Sep 04, 2026, 12:07 PM UTC
L
IOVA - Iovance Biotherapeutics to Present at Upcoming Conferences
IOVA - Iovance Biotherapeutics to Present at Upcoming Conferences
EQUITY | Sep 04, 2026, 12:00 PM UTC
L
Iovance Biotherapeutics reports inducement grants under NASDAQ Rule 5635(c)(4)
Iovance Biotherapeutics (IOVA) reports inducement grants issued under NASDAQ Listing Rule 5635(c)(4), according to the company filing referenced by TradeXchange Newsdesk.
REGULATION | Aug 21, 2026, 09:15 PM UTC
L
IOVA highs +12%
IOVA highs +12%
EQUITY | Aug 20, 2026, 06:55 PM UTC
H
Iovance Biotherapeutics trades at 52-week high after sector-linked momentum
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) is trading at a 52-week high despite no company-specific news, while the post also cites second-quarter results and reaffirmed fiscal 2026 sales guidance.
EARNINGS | Aug 20, 2026, 05:14 PM UTC
L
BAP BILL CPB IOVA JKHY MRK MRNA MRVL NU SJM TGT TJX TOL ZM LOW MAR PT changes @ UBS
BAP BILL CPB IOVA JKHY MRK MRNA MRVL NU SJM TGT TJX TOL ZM LOW MAR PT changes @ UBS
EQUITY | Aug 20, 2026, 11:04 AM UTC
H
IOVA rallies to highs, +13.75% above $8
IOVA trades at new highs, up 13.75% above $8 to its best level since December 2024, according to Hammerstone MarketTalk.
EQUITY | Aug 19, 2026, 07:40 PM UTC
L
Iovance (IOVA) Stock Soars After Better-Than-Expected Q2 Results
Iovance Biotherapeutics Inc (NASDAQ: IOVA ) shares are surging Thursday after the cancer therapy company beat second-quarter expectations on both the top and bottom lines. Here’s what you should know. Iovance Biotherapeu
EARNINGS | Aug 06, 2026, 06:06 PM UTC
H
Motorola Solutions Posts Upbeat Q2 Earnings, Joins Insmed, Diodes, Parker-Hannifin And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Thursday. Shares of Motorola Solutions In c (NYSE: MSI ) rose sharply after the company reported better-than-expected second-quarter financial
EARNINGS | Aug 06, 2026, 02:01 PM UTC
L
Iovance Biotherapeutics Affirms FY2026 Sales Guidance of $350.000M-$370.000M vs $362.083M Est
Iovance Biotherapeutics (NASDAQ: IOVA ) affirms FY2026 sales outlook from $350.000 million-$370.000 million to $350.000 million-$370.000 million vs $362.083 million estimate.
EARNINGS | Aug 06, 2026, 11:11 AM UTC
H
Iovance Biotherapeutics Reports Record Revenue
Iovance reports $99M revenue in Q2 2026
EQUITY | Aug 06, 2026, 11:01 AM UTC
H
IOVA falls 8.4% on REPL melanoma treatment
IOVA shares drop on competing treatment news
EQUITY | Jul 31, 2026, 02:38 PM UTC
L
IOVA - Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026 - Click For
IOVA - Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026
EARNINGS | Jul 30, 2026, 12:00 PM UTC
M
BIVI Files $300M Mixed Shelf
BIVI and other companies file mixed shelf offerings with the SEC
EQUITY | Jun 22, 2026, 09:29 AM UTC
L
IOVA Files Mixed Shelf
IOVA files a mixed shelf offering with the SEC
EQUITY | Jun 18, 2026, 08:32 PM UTC